4 Firms Lead Cancer-Centric Biotechs In IPOs Totaling $459M
A pair of cancer-focused biotechnology companies saw their share prices pop on Friday after market debuts that raised a combined $459 million, with guidance from Goodwin, Cooley, Harney Westwood and AllBright...To view the full article, register now.
Already a subscriber? Click here to view full article